21 related articles for article (PubMed ID: 38504986)
1. Identifying disulfidptosis subtypes in hepatocellular carcinoma through machine learning and preliminary exploration of its connection with immunotherapy.
Chen G; Zhang G; Zhu Y; Wu A; Fang J; Yin Z; Chen H; Cao K
Cancer Cell Int; 2024 Jun; 24(1):194. PubMed ID: 38831301
[TBL] [Abstract][Full Text] [Related]
2. A novel disulfidptosis-related gene signature predicts overall survival of glioblastoma patients.
Zhang Y; Liu B; Zhou Y
Future Sci OA; 2024; 10(1):FSO948. PubMed ID: 38817361
[TBL] [Abstract][Full Text] [Related]
3. RNA sequencing-based approaches to identifying disulfidptosis-related diagnostic clusters and immune landscapes in osteoporosis.
Zhang P; Li B; Chen H; Ge Z; Shang Q; Liang D; Yu X; Ren H; Jiang X; Cui J
Aging (Albany NY); 2024 May; 16(9):8198-8216. PubMed ID: 38738994
[TBL] [Abstract][Full Text] [Related]
4. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
7. Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma.
Zhou Y; Cao Y; Liu W; Wang L; Kuang Y; Zhou Y; Chen Q; Cheng Z; Huang H; Zhang W; Jiang X; Wang B; Ren C
Front Immunol; 2023; 14():1294459. PubMed ID: 38162649
[TBL] [Abstract][Full Text] [Related]
8. Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma.
Liu J; Li H; Zhang N; Dong Q; Liang Z
Curr Med Chem; 2024 Apr; ():. PubMed ID: 38685772
[TBL] [Abstract][Full Text] [Related]
9. Development and experimental verification of a prognosis model for disulfidptosis-associated genes in HNSCC.
Li Y; Tao L; Xin J; Dai Y; Chen X; Zou J; Wang R; Wang B; Liu Z
Medicine (Baltimore); 2024 Mar; 103(12):e37308. PubMed ID: 38518012
[TBL] [Abstract][Full Text] [Related]
10. Disulfidptosis decoded: a journey through cell death mysteries, regulatory networks, disease paradigms and future directions.
Chen J; Ma B; Yang Y; Wang B; Hao J; Zhou X
Biomark Res; 2024 Apr; 12(1):45. PubMed ID: 38685115
[TBL] [Abstract][Full Text] [Related]
11. Integrated multiomic analysis reveals disulfidptosis subtypes in glioblastoma: implications for immunotherapy, targeted therapy, and chemotherapy.
Yang X; Cai Z; Wang C; Jiang C; Li J; Chen F; Li W
Front Immunol; 2024; 15():1362543. PubMed ID: 38504986
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
